Cyclooxygenase enzymes in allergic inflammation and asthma

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 69, Issue 2-3, 2003, Pages 157-162

  Carey, Michelle A ^a   Germolec, Dori R ^a   Langenbach, Robert ^a   Zeldin, Darryl C ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ICOSANOID; PROSTACYCLIN; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PROSTANOID RECEPTOR; THROMBOXANE A2;

ALLERGIC PNEUMONITIS; ALLERGY; ASTHMA; HUMAN; LIPOGENESIS; LUNG FUNCTION; PATHOGENESIS; PATHOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; REVIEW;

EID: 0042122475     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-3278(03)00076-0     Document Type: Article

References (77)

1. C.D. Funk, Prostaglandins and leukotrienes: advances in eicosanoid biology, Science 294 (2001) 1871-1875.
2. W.L. Smith, D.L. DeWitt, R.M. Garavito, Cyclooxygenases: structural, cellular, and molecular biology, Annu. Rev. Biochem. 69 (2000) 145-182.
3. W.L. Smith, D.L. Dewitt, Prostaglandin endoperoxide H synthases-1 and -2, Adv. Immunol. 62 (1996) 167-215.
4. B.S. Chan, J.A. Satriano, M. Pucci, V.L. Schuster, Mechanism of prostaglandin E2 transport across the plasma membrane of HeLa cells and Xenopus oocytes expressing the prostaglandin transporter "PGT", J. Biol. Chem. 273 (1998) 6689-6697.
5. Y. Sugimoto, E. Segi, K. Tsuboi, A. Ichikawa, S. Narumiya, Female reproduction in mice lacking the prostaglandin F receptor. Roles of prostaglandin and oxytocin receptors in parturition, Adv. Exp. Med. Biol. 449 (1998) 317-321.
6. T. Murata, F. Ushikubi, T. Matsuoka, et al., Altered pain perception and inflammatory response in mice lacking prostacyclin receptor, Nature 388 (1997) 678-682.
7. H. Lim, R.A. Gupta, W.G. Ma, et al., Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta, Genes Dev. 13 (1999) 1561-1574.
8. R.M. Breyer, C.K. Bagdassarian, S.A. Myers, M.D. Breyer, Prostanoid receptors: subtypes and signaling, Annu. Rev. Pharmacol. Toxicol. 41 (2001) 661-690.
9. M.A. Wasserman, Modulation of arachidonic acid metabolites as potential therapy of asthma, Agents Actions Suppl. 23 (1988) 95-111.
10. S.G. Morham, R. Langenbach, C.D. Loftin, et al., Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse, Cell 83 (1995) 473-482.
11. S.L. Tilley, T.M. Coffman, B.H. Koller, Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes, J. Clin. Invest. 108 (2001) 15-23.
12. 2 selectively induces chemotaxis in T helper type 2 cells eosinophils and basophils via seven-transmembrane receptor CRTH2, J. Exp. Med. 193 (2001) 255-261.
13. B. Mayr, M. Montminy, Transcriptional regulation by the phosphorylation-dependent factor CREB, Nat. Rev. Mol. Cell Biol. 2 (2001) 599-609.
14. S.G. Harris, J. Padilla, L. Koumas, D. Ray, R.P. Phipps, Prostaglandins as modulators of immunity, Trends Immunol. 23 (2002) 144-150.
15. C. Nataraj, D.W. Thomas, S.L. Tilley, et al., Receptors for prostaglandin E(2) that regulate cellular immune responses in the mouse, J. Clin. Invest. 108 (2001) 1229-1235.
16. J. Pene, F. Rousset, F. Briere, et al., IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons gamma and alpha and prostaglandin E2, Proc. Natl. Acad. Sci. USA 85 (1988) 6880-6884.
17. M.M. Khan, Regulation of IL-4 and IL-5 secretion by histamine and PGE2, Adv. Exp. Med. Biol. 383 (1995) 35-42.
18. M.C. Liu, E.R. Bleecker, L.M. Lichtenstein, et al., Evidence for elevated levels of histamine, prostaglandin D2, and other bronchoconstricting prostaglandins in the airways of subjects with mild asthma, Am. Rev. Respir. Dis. 142 (1990) 126-132.
19. J.C. McGuire, F.F. Sun, Metabolism of arachidonic acid and prostaglandin endoperoxide by assorted leukocytes, Adv. Prostaglandin Thromboxane Res. 8 (1980) 1665-1667.
20. C. Kroegel, H. Matthys, Platelet-activating factor-induced human eosinophil activation. Generation and release of cyclo-oxygenase metabolites in human blood eosinophils from asthmatics, Immunology 78 (1993) 279-285.
21. S.T. Holgate, G.B. Burns, C. Robinson, M.K. Church, Anaphylactic- and calcium-dependent generation of prostaglandin D2 (PGD2), thromboxane B2, and other cyclooxygenase products of arachidonic acid by dispersed human lung cells and relationship to histamine release, J. Immunol. 133 (1984) 2138-2144.
22. K. Tanaka, K. Ogawa, K. Sugamura, M. Nakamura, S. Takano, K. Nagata, Cutting edge: differential production of prostaglandin D2 by human helper T cell subsets, J. Immunol. 164 (2000) 2277-2280.
23. J.J. Murray, A.B. Tonnel, A.R. Brash, et al., Release of prostaglandin D2 into human airways during acute antigen challenge, N. Engl. J. Med. 315 (1986) 800-804.
24. P.J. Gardiner, H.O. Collier, Specific receptors for prostaglandins in airways, Prostaglandins 19 (1980) 819-841.
25. C.R. Beasley, C. Robinson, R.L. Featherstone, et al., 9Alpha, 11 beta-prostaglandin F2 a novel metabolite of prostaglandin D2 is a potent contractile agonist of human and guinea pig airways, J. Clin. Invest. 79 (1987) 978-983.
26. C.C. Hardy, C. Robinson, A.E. Tattersfield, S.T. Holgate, The bronchoconstrictor effect of inhaled prostaglandin D2 in normal and asthmatic men, N. Engl. J. Med. 311 (1984) 209-213.
27. A.A. Mathe, P. Hedqvist, Effect of prostaglandins F2 alpha and E2 on airway conductance in healthy subjects and asthmatic patients, Am. Rev. Respir. Dis. 111 (1975) 313-320.
28. 2 potentiates airway responsiveness to histamine and methacholine, Am. Rev. Respir. Dis. 133 (1986) 252-254.
29. Y. Fujitani, Y. Kanaoka, K. Aritake, N. Uodome, K. Okazaki-Hatake, Y. Urade, Pronounced eosinophilic lung inflammation and Th2 cytokine release in human lipocalin-type prostaglandin D synthase transgenic mice, J. Immunol. 168 (2002) 443-449.
30. 2 as a mediator of allergic asthma, Science 287 (2000) 2013-2017.
31. 2 by bovine cultured airway smooth muscle cells: regulation by camp, J. Appl. Physiol. 78 (1995) 623-628.
32. F. Delamere, E. Holland, S. Patel, J. Bennett, I. Pavord, A. Knox, Production of PGE2 by bovine cultured airway smooth muscle cells and its inhibition by cyclo-oxygenase inhibitors, Br. J. Pharmacol. 111 (1994) 983-988.
33. L. Pang, A.J. Knox, Effect of interleukin-1 beta, tumour necrosis factor-alpha and interferon-gamma on the induction of cyclooxygenase-2 in cultured human airway smooth muscle cells, Br. J. Pharmacol. 121 (1997) 579-587.
34. M.G. Belvisi, M.A. Saunders, B. Haddad el, et al., Induction of cyclo-oxygenase-2 by cytokines in human cultured airway smooth muscle cells: novel inflammatory role of this cell type, Br. J. Pharmacol. 120 (1997) 910-916.
35. S.P. Peters, E.S. Schulman, R.P. Schleimer, D.W. MacGlashan, H.H. Newball Jr., L.M. Lichtenstein, Dispersed human lung mast cells. Pharmacologic aspects and comparison with human lung tissue fragments, Am. Rev. Respir. Dis. 126 (1982) 1034-1039.
36. H. Kita, R.I. Abu-Ghazaleh, G.J. Gleich, R.T. Abraham, Regulation of Ig-induced eosinophil degranulation by adenosine-3′,5′-cyclic monophosphate, J. Immunol. 146 (1991) 2712-2718.
37. R. Alam, A. Dejarnatt, S. Stafford, P.A. Forsythe, D. Kumar, J.A. Grant, Selective inhibition of the cutaneous late but not immediate allergic response to antigens by misoprostol, a PGE analog Results of a double-blind, placebo-controlled randomized study, Am. Rev. Respir. Dis. 148 (1993) 1066-1070.
38. 2 suppression of acetylcholine release from parasympathetic nerves innervating guinea-pig trachea by interacting with prostanoid receptors of the EP3-subtype, Br. J. Pharmacol. 123 (1998) 1246-1252.
39. 2 on allergen-induced airway responses and airway inflammation, Am. J. Respir. Crit. Care Med. 159 (1999) 31-36.
40. I.D. Pavord, C.S. Wong, J. Williams, A.E. Tattersfield, Effect of inhaled prostaglandin E2 on allergen-induced asthma, Am. Rev. Respir. Dis. 148 (1993) 87-90.
41. E. Melillo, K.L. Woolley, P.J. Manning, R.M. Watson, P.M. O'Byrne, Effect of inhaled PGE2 on exercise-induced bronchoconstriction in asthmatic subjects, Am. J. Respir. Crit. Care Med. 149 (1994) 1138-1141.
42. 2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma, Am. J. Respir. Crit. Care Med. 153 (1996) 572-575.
43. C. Hardy, C. Robinson, R.A. Lewis, A.E. Tattersfield, S.T. Holgate, Airway and cardiovascular responses to inhaled prostacyclin in normal and asthmatic subjects, Am. Rev. Respir. Dis. 131 (1985) 18-21.
44. S. Bianco, M. Robuschi, R. Ceserani, C. Gandolfi, Effects of prostacyclin on aspecifically and specifically induced bronchoconstriction in asthmatic patients, Eur. J. Respir. Dis. Suppl. 106 (1980) 81-87.
45. C.C. Hardy, P. Bradding, C. Robinson, S.T. Holgate, Bronchoconstrictor and antibronchoconstrictor properties of inhaled prostacyclin in asthma, J. Appl. Physiol. 64 (1988) 1567-1574.
46. P. Demoly, D. Jaffuel, N. Lequeux, et al., Prostaglandin H synthase 1 and 2 immunoreactivities in the bronchial mucosa of asthmatics, Am. J. Respir. Crit. Care Med. 155 (1997) 670-675.
47. J.C. Bonner, A.B. Rice, J.L. Ingram, et al., Susceptibility of cyclooxygenase-2-deficient mice to pulmonary fibrogenesis, Am. J. Pathol. 161 (2002) 459-470.
48. A. Sousa, R. Pfister, P.E. Christie, et al., Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma, Thorax 52 (1997) 940-945.
49. R. Taha, R. Olivenstein, T. Utsumi, et al., Prostaglandin H synthase 2 expression in airway cells from patients with asthma and chronic obstructive pulmonary disease, Am. J. Respir. Crit. Care Med. 161 (2000) 636-640.
50. R. Langenbach, S.G. Morham, H.F. Tiano, et al., Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration, Cell 83 (1995) 483-492.
51. S.H. Gavett, S.L. Madison, P.C. Chulada, et al., Allergic lung responses are increased in prostaglandin H synthase-deficient mice, J. Clin. Invest. 104 (1999) 721-732.
52. D.C. Zeldin, C. Wohlford-Lenane, P. Chulada, et al., Airway inflammation and responsiveness in prostaglandin H synthase-deficient mice exposed to bacterial lipopolysaccharide, Am. J. Respir. Cell Mol. Biol. 25 (2001) 457-465.
53. A.M. Bento, M.B. Hershenson, Airway remodeling: potential contributions of subepithelial fibrosis and airway smooth muscle hypertrophy/hyperplasia to airway narrowing in asthma, Allergy Asthma Proc. 19 (1998) 353-358.
54. Q. Hamid, M. Azzawi, S. Ying, et al., Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma, J. Clin. Invest. 87 (1991) 1541-1546.
55. D.S. Robinson, Q. Hamid, S. Ying, et al., Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma, N. Engl. J. Med. 326 (1992) 298-304.
56. M. Wills-Karp, J. Luyimbazi, X. Xu, et al., Interleukin-13: central mediator of allergic asthma, Science 282 (1998) 2258-2261.
57. 2 inhibits production of Th1 lymphokines but not of Th2 lymphokines, J. Immunol. 146 (1991) 108-113.
58. K. Katamura, N. Shintaku, Y. Yamauchi, et al., Prostaglandin E2 at priming of naive CD4 + T cells inhibits acquisition of ability to produce IFN-gamma and IL-2 but not IL-4 and IL-5, J. Immunol. 155 (1995) 4604-4612.
59. 2 and dexamethasone inhibit IL-12 receptor expression and IL-12 responsiveness, J. Immunol. 161 (1998) 2723-2730.
60. J.L. Perez-Santos, P. Talamas-Rohana, In vitro indomethacin administration upregulates interleukin-12 production and polarizes the immune response towards a Th1 type in susceptible BALB/c mice infected with Leishmania mexicana, Parasite Immunol. 23 (2001) 599-606.
61. R.S. Peebles Jr, R. Dworski, R.D. Collins, et al., Cyclooxygenase inhibition increases interleukin 5 and interleukin 13 production and airway hyperresponsiveness in allergic mice, Am. J. Respir. Crit. Care Med. 162 (2000) 676-681.
62. R.S. Peebles Jr, K. Hashimoto, J.D. Morrow, et al., Selective cyclooxygenase-1 and -2 inhibitors each increase allergic inflammation and airway hyperresponsiveness in mice, Am. J. Respir. Crit. Care Med. 165 (2002) 1154-1160.
63. J.A. Mitchell, P. Akarasereenont, C. Thiemermann, R.J. Flower, J.R. Vane, Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase, Proc. Natl. Acad. Sci. USA 90 (1993) 11693-11697.
64. A. Szczeklik, D.D. Stevenson, Aspirin-induced asthma: advances in pathogenesis and management, J. Allergy Clin. Immunol. 104 (1999) 5-13.
65. J. Quiralte, C. Blanco, R. Castillo, J. Delgado, T. Carrillo, Intolerance to nonsteroidal antiinflammatory drugs: results of controlled drug challenges in 98 patients, J. Allergy Clin. Immunol. 98 (1996) 678-685.
66. C. Picado, J.A. Castillo, J.M. Montserrat, A. Agusti-Vidal, Aspirin-intolerance as a precipitating factor of life-threatening attacks of asthma requiring mechanical ventilation, Eur. Respir. J. 2 (1989) 127-129.
67. A. Szczeklik, The cyclooxygenase theory of aspirin-induced asthma, Eur. Respir. J. 3 (1990) 588-593.
68. W.W. Busse, The role of leukotrienes in asthma and allergic rhinitis, Clin. Exp. Allergy 26 (1996) 868-879.
69. A.P. Sampson, The leukotrienes: mediators of chronic inflammation in asthma, Clin. Exp. Allergy 26 (1996) 995-1004.
70. M. Sanak, A.P. Sampson, Biosynthesis of cysteinyl-leucotrienes in aspirin-intolerant asthma, Clin. Exp. Allergy 29 (1999) 306-313.
71. P.E. Christie, C.M. Smith, T.H. Lee, The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma, Am. Rev. Respir. Dis. 144 (1991) 957-958.
72. A. Szczeklik, K. Sladek, R.J. Dworski, et al., Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics, Am. J. Respir. Crit. Care Med. 154 (1996) 1608-1614.
73. S. Bianco, M. Robuschi, G. Petrigni, et al., Efficacy and tolerability of nimesulide in asthmatic patients intolerant to aspirin, Drugs 46 (1993) 115-120.
74. M. Kosnik, E. Music, F. Matjaz, S. Suskovic, Relative safety of meloxicam in NSAID-intolerant patients, Allergy 53 (1998) 1231-1233.
75. B. Dahlen, A. Szczeklik, J.J. Murray, Celecoxib in patients with asthma and aspirin intolerance. The celecoxib in aspirin-intolerant asthma study group, N. Engl. J. Med. 344 (2001) 142.
76. C. Martin-Garcia, M. Hinojosa, P. Berges, et al., Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma, Chest 121 (2002) 1812-1817.
77. -/- mice, Am. J. Respir. Crit. Care Med., 2003, in press.